Menu Search
Equities

Moberg Pharma AB (publ)

MB8:MUN

Moberg Pharma AB (publ)

Actions
  • Price (EUR)1.63
  • Today's Change-0.021 / -1.24%
  • Shares traded2.00k
  • 1 Year change+108.03%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Moberg Pharma AB (publ)'s revenues fell -100.00% from 207.00k to 0.00. has fallen 34.26% from a loss of 15.71m to a larger loss of 21.09m.
Gross margin73.46%
Net profit margin-207.75%
Operating margin-283.86%
Return on assets-2.30%
Return on equity-2.36%
Return on investment-2.35%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Moberg Pharma AB (publ) fell by 65.00m. Cash Flow from Financing totalled 92.33m or -- of revenues. In addition the company used 33.21m for operations while cash used for investing totalled 124.12m.
Cash flow per share-0.5126
Price/Cash flow per share--
Book value per share19.89
Tangible book value per share7.31
More ▼

Balance sheet in SEKView more

Moberg Pharma AB (publ) has little financial risk as the capital structure does not rely on leverage.
Current ratio22.52
Quick ratio22.03
Total debt/total equity0.004
Total debt/total capital0.0039
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.